These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38104128)

  • 1. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR
    Solomon GM; Linnemann RW; Rich R; Streby A; Buehler B; Hunter E; Vijaykumar K; Hunt WR; Brewington JJ; Rab A; Bai SP; Westbrook AL; McNicholas-Bevensee C; Hong J; Manfredi C; Barilla C; Suzuki S; Davis BR; Sorscher EJ
    Lancet Respir Med; 2024 Dec; 12(12):947-957. PubMed ID: 39208836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Res Sq; 2023 Sep; ():. PubMed ID: 37841851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Experience Sampling Methodology to Capture Disclosure Opportunities for Autistic Adults.
    Love AMA; Edwards C; Cai RY; Gibbs V
    Autism Adulthood; 2023 Dec; 5(4):389-400. PubMed ID: 38116059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor/Tezacaftor/Ivacaftor treatment - A Danish prospective cohort.
    Philipsen LKD; Olesen HV; Jensen JH; Olsen MF; Faurholt-Jepsen D; Buchvald F; Nielsen KG; Skov M; Pressler T
    J Cyst Fibros; 2024 Nov; 23(6):1080-1086. PubMed ID: 38697864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Field Theory of Executive Function: Identifying Early Neurocognitive Markers.
    McCraw A; Sullivan J; Lowery K; Eddings R; Heim HR; Buss AT
    Monogr Soc Res Child Dev; 2024 Dec; 89(3):7-109. PubMed ID: 39628288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT.
    Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C
    Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel function.
    Hampton TH; Barnaby R; Roche C; Nymon A; Fukutani KF; MacKenzie TA; Charpentier LA; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2024 Dec; 327(6):L905-L916. PubMed ID: 39437760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
    Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.
    Manes TJ; DeGenova DT; Taylor BC; Patel JN
    JBJS Essent Surg Tech; 2024; 14(4):. PubMed ID: 39650795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease.
    Protich HE; Molleston JP; Bozic M; Pettit RS
    J Cyst Fibros; 2024 Nov; 23(6):1122-1128. PubMed ID: 38580564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.
    Milczewska J; Syunyaeva Z; Żabińska-Jaroń A; Sands D; Thee S
    Eur Respir Rev; 2024 Oct; 33(174):. PubMed ID: 39631927
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.